Abstract
Daptomycin may offer an antibacterial alternative for the treatment of endophthalmitis caused by methicillin-resistant Staphylococcus aureus (MRSA) and other potential agents. In the present project, mucoadhesive chitosan-coated alginate (CS-ALG) nanoparticles are proposed as an effective delivery system for daptomycin permeation across ocular epithelia, with potential for the treatment of bacterial endophthalmitis. CS-ALG nanoparticles were prepared by ionotropic pre-gelation of an alginate core followed by chitosan polyelectrolyte complexation, and characterized regarding particle size, polydispersity, and zeta potential. The encapsulation efficiency was determined and antimicrobial activity was also tested after encapsulation of the antibiotic. Also, in vitro ocular permeability of free daptomycin and encapsulation into chitosan and CS-ALG nanoparticles was evaluated using ocular epithelial cell culture models. Formulated daptomycin-loaded CS-ALG nanoparticles were negatively charged, with a size range of 380–420 nm, suitable for ocular application. The encapsulation efficiency was between 79 and 92 %, with decreasing alginate:daptomycin mass ratios. The antibacterial activity of daptomycin against major microorganisms responsible for bacterial endophthalmitis was not affected by encapsulation into nanoparticles. Daptomycin permeability was up to 16 % (chitosan nanoparticles) and 9 % (CS-ALG nanoparticles) through corneal cell monolayer, and 18 % (chitosan nanoparticles) and 12 % (CS-ALG nanoparticles) for retinal cell monolayer after 4 h, demonstrating epithelial retention of the drug compared to free drug. The developed daptomycin-loaded CS-ALG nanoparticles seem to be an interesting and potential system for ocular daptomycin delivery and treatment of bacterial endophthalmitis.
Similar content being viewed by others
References
Callegan MC, Engelbert M, Parke DW 2nd, Jett BD, Gilmore MS (2002) Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium–host interactions. Clin Microbiol Rev 15:111–124
Kunimoto DY, Das T, Sharma S, Jalali S, Majji AB, Gopinathan U, Athmanathan S, Rao TN (1999) Microbiologic spectrum and susceptibility of isolates: part I. Postoperative endophthalmitis. Endophthalmitis Research Group. Am J Ophthalmol 128:240–242
Callegan MC, Gilmore MS, Gregory M, Ramadan RT, Wiskur BJ, Moyer AL, Hunt JJ, Novosad BD (2007) Bacterial endophthalmitis: therapeutic challenges and host–pathogen interactions. Prog Retin Eye Res 26:189–203
Jeu L, Fung HB (2004) Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin Ther 26:1728–1757
Enoch DA, Bygott JM, Daly ML, Karas JA (2007) Daptomycin. J Infect 55:205–213
Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58:1131–1135
de la Fuente M, Raviña M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ (2010) Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 62:100–117
Silva NC, Silva S, Sarmento B, Pintado M (2013) Chitosan nanoparticles for daptomycin delivery in ocular treatment of bacterial endophthalmitis. Drug Deliv ID:858195. doi:10.3109/10717544.2013.858195
Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK (2008) Chitosan–sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 68:513–525
Nagarwal RC, Kumar R, Pandit JK (2012) Chitosan coated sodium alginate–chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye. Eur J Pharm Sci 47:678–685
Yan XL, Khor E, Lim LY (2001) Chitosan–alginate films prepared with chitosans of different molecular weights. J Biomed Mater Res 58:358–365
de Campos AM, Diebold Y, Carvalho ELS, Sánchez A, Alonso MJ (2004) Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res 21:803–810
Liu W, Griffith M, Li F (2008) Alginate microsphere–collagen composite hydrogel for ocular drug delivery and implantation. J Mater Sci Mater Med 19:3365–3371
Liu S, Jones L, Gu FX (2012) Nanomaterials for ocular drug delivery. Macromol Biosci 12:608–620
Sangeetha S, Venkatesh DN, Adhiyaman R, Santhi K, Suresh B (2007) Formulation of sodium alginate nanospheres containing amphotericin B for the treatment of systemic candidiasis. Trop J Pharm Res 6:653–659
Ding S (1998) Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today 1:328–335
Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK (2009) Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 136:2–13
Mi FL, Tan YC, Liang HF, Sung HW (2002) In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant. Biomaterials 23:181–191
Tamboli V, Mishra GP, Mitra AK (2012) Biodegradable polymers for ocular drug delivery. Adv Ocul Drug Deliv 2012:65–86
Severino P, Vasconcellos FC, Figueiredo ES (2007) Uso tópico de quitosana em oftalmologia. Rev Bras Farm 88:155–158
Mourya VK, Inamdar NN (2008) Chitosan-modifications and applications: opportunities galore. React Funct Polym 68:1013–1051
Subramanian A, Vasanthan KS, Krishnan UM, Sethuraman S (2011) Chitosan and its derivatives in clinical use and applications. In: Domb AJ, Kumar N, Ezra A (eds) Biodegradable polymers in clinical use and clinical development. Wiley, New Jersey, pp 113–135
Zahoor A, Sharma S, Khuller GK (2005) Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 26:298–303
Sarmento B, Ribeiro A, Veiga F, Ferreira D (2006) Development and validation of a rapid reversed-phase HPLC method for the determination of insulin from nanoparticulate systems. Biomed Chromatogr 20:898–903
Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D (2007) Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 24:2198–2206
Clinical and Laboratory Standards Institute (CLSI) (2003) Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, NCCLS document M7-A6, 6th edition. Villanova, Pennsylvania, USA
Clinical and Laboratory Standards Institute (CLSI) (2005) Performance standards for antimicrobial susceptibility testing, 15th informational supplement, NCCLS document M100-S15. Villanova, Pennsylvania, USA
Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM (1996) ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 62:155–169
Barar J, Asadi M, Mortazavi-Tabatabaei SA, Omidi Y (2009) Ocular drug delivery impact of in vitro cell culture models. J Ophthalmic Vis Res 4:238–252
Geiger RC, Waters CM, Kamp DW, Glucksberg MR (2005) KGF prevents oxygen-mediated damage in ARPE-19 cells. Invest Ophthalmol Vis Sci 46:3435–3442
Zimmer A, Kreuter J (1995) Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 16:61–73
Hans ML, Lowman AM (2002) Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 6:319–327
Chen A, Haddad D, Wang R (2009) Analysis of chitosan-alginate bone scaffolds. Rutgers University, New Jersey Governor’s School of Engineering & Technology
Harnsilawat T, Pongsawatmanit R, McClements DJ (2006) Characterization of β-lactoglobulin–sodium alginate interactions in aqueous solutions: a calorimetry, light scattering, electrophoretic mobility and solubility study. Food Hydrocoll 20:577–585
Nagpal K, Singh SK, Mishra DN (2010) Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo) 58:1423–1430
Barry AL, Fuchs PC, Brown SD (2001) In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 45:1919–1922
Fuchs PC, Barry AL, Brown SD (2002) In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 49:467–470
Fluit AC, Schmitz FJ, Verhoef J, Milatovic D (2004) In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 48:1007–1011
Hornof M, Toropainen E, Urtti A (2005) Cell culture models of the ocular barriers. Eur J Pharm Biopharm 60:207–225
Mannermaa E, Reinisalo M, Ranta V-P, Vellonen K-S, Kokki H, Saarikko A, Kaarniranta K, Urtti A (2010) Filter-cultured ARPE-19 cells as outer blood–retinal barrier model. Eur J Pharm Sci 40:289–296
Nagai N, Ito Y, Okamoto N, Shimomura Y (2014) A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. Toxicology 319:53–62
Antunes F, Andrade F, Araújo F, Ferreira D, Sarmento B (2013) Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur J Pharm Biopharm 83:427–435
Diebold Y, Calonge M (2010) Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 29:596–609
De Campos AM, Sánchez A, Alonso MJ (2001) Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 224:159–168
Acknowledgments
This work was supported by National Funds from FCT through project PEst-OE/EQB/LA0016/2013. The authors would like to thank Cubist Pharmaceuticals, Inc. and Novartis Pharma AG for providing the daptomycin.
Conflict of interest
The authors report no conflict of interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Costa, J., Silva, N.C., Sarmento, B. et al. Potential chitosan-coated alginate nanoparticles for ocular delivery of daptomycin. Eur J Clin Microbiol Infect Dis 34, 1255–1262 (2015). https://doi.org/10.1007/s10096-015-2344-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-015-2344-7